

Analysis of Fumonisin B₁-Induced Apoptosis

Clinton Jones,¹ Janice R. Ciacci-Zanella,¹ Yange Zhang,^{1,2} Gail Henderson,¹ and Martin Dickman²

¹Center for Biotechnology, Department of Veterinary and Biomedical Sciences, University of Nebraska-Lincoln, East Campus Loop, Lincoln, Nebraska, USA; ²Department of Plant Pathology, University of Nebraska-Lincoln, East Campus Loop, Lincoln, Nebraska, USA

Fumonisin is a mycotoxin produced by *Fusarium moniliforme*, a prevalent fungus that infects corn and other cereal grains. Fumonisin B₁ (FB₁) is the most common mycotoxin produced by *F. moniliforme*, suggesting it has toxicologic significance. The structure of FB₁ resembles sphingoid bases, and it inhibits ceramide synthase. Because sphingoid bases regulate cell growth, differentiation, transformation, and apoptosis, it is not surprising to find that FB₁ can alter growth of certain mammalian cells. Previous studies concluded FB₁-induced apoptosis, or cell cycle arrest, in African green monkey kidney fibroblasts (CV-1). In this study we have identified genes that inhibit FB₁-induced apoptosis in CV-1 cells and two mouse embryo fibroblasts (MEF). A baculovirus gene, inhibitor of apoptosis (CpIAP), protected these cells from apoptosis. CpIAP blocks apoptosis induced by the tumor necrosis factor (TNF) pathway as well as other mechanisms. Further support for the involvement of the TNF signal transduction pathway in FB₁-induced apoptosis was the cleavage of caspase 8. Inhibition of caspases by the baculovirus gene *p35* also inhibited FB₁-induced apoptosis. The tumor suppressor gene *p53* was not required for FB₁-induced apoptosis because *p53*^{-/-} MEF undergo apoptosis following FB₁ treatment. Furthermore, *Bcl-2* was not an effective inhibitor of FB₁-induced apoptosis in CV-1 cells or *p53*^{+/+} MEF. In summary, these results provide new information to help understand the mechanism by which FB₁ induces apoptosis. **Key words:** apoptosis, fumonisin B₁, mycotoxins, signal transduction, tumor necrosis factor. — *Environ Health Perspect* 109(suppl 2):315–320 (2001).

<http://ehpnet1.niehs.nih.gov/docs/2001/suppl-2/315-320jones/abstract.html>

Introduction

Fusarium moniliforme is a significant plant pathogen that primarily infects corn but can also infect rice and wheat [reviewed in (1–7)]. The fungus is widespread and produces a variety of mycotoxins; the major class is called fumonisin. Several subtypes of fumonisin have been identified (A, B, or C), and all these compounds resemble sphingolipids [reviewed in (8–10)]. FB₁ inhibits sphingosine *N*-acetyltransferase (ceramide synthase) and thus blocks sphingolipid biosynthesis. FB₁ and FB₂ are of toxicologic significance because they are present at high concentrations on diseased plants and are frequently detected on healthy corn plants (11).

Ingestion of moldy corn infected by *F. moniliforme* or closely related fungi is linked to a higher incidence of primary liver cancer (12) and esophageal cancer in regions of South Africa and China (13). In rats fed a diet containing 50 mg/kg FB₁, primary hepatocellular carcinoma occurred in two thirds of the animals (14–16). FB₁ is also a potent tumor promoter in rat liver after initiation with diethylnitrosamine (17). Cancer-promoting activity has occurred at levels that did not induce liver or kidney toxicity and, furthermore, did not initiate cancer.

Culture material from *F. moniliforme* containing FB₁ induces equine leukoencephalomalacia and nephrotoxicity (18). Purified preparations of FB₁ are also hepatotoxic (19), cause porcine pulmonary edema (20), and are nephrotoxic to several animal species

(21–23). *In vivo* studies have demonstrated that FB₁ induces apoptosis in rat kidney and liver (24–26). FB₁ also induces apoptosis of several different mammalian cell types (26–29), demonstrating that treatment can lead directly to apoptosis. A previous study demonstrated that neoplastic African green monkey kidney cells (COS-7) are resistant to the apoptotic and antiproliferative effects of FB₁ compared to their normal counterparts, African green monkey kidney cells (CV-1) (29,30). Murine or human leukemia cells do not undergo apoptosis when treated with FB₁ (30,31). We have also found that other cell lines derived from human tumors are resistant to the effects of FB₁ (data not shown). Taken together, these studies suggested that transformed cells, in general, are resistant to the effects of FB₁. Because the ability of cells to escape apoptosis plays a critical role in the development of cancer, the ability of FB₁ to induce apoptosis may select for cells resistant to apoptosis. It is hypothesized that these cells would have altered growth capabilities.

The goal of this study was to characterize FB₁-induced apoptosis. A previous study demonstrated that cyclin-dependent kinase (cdk) activity increased slightly after 3 hr of FB₁ treatment but then declined (30). This is significant because cdk activity transiently increases during the early stages of apoptosis (32). Further studies confirmed that cdk2 activity transiently increased after FB₁ treatment. Several pathways have been identified that result in programmed cell death or

apoptosis [reviewed in (33)]. A quantitative assay for apoptosis was used to identify specific genes that interfere with FB₁-induced apoptosis. This assay indicated that a baculovirus gene (CpIAP) inhibited FB₁-induced apoptosis. Because CpIAP inhibits tumor necrosis factor (TNF)-induced apoptosis, we further examined other factors involved in TNF signal transduction pathways. A caspase involved with TNF-induced apoptosis (caspase 8) was cleaved and activated within 2 hr after treatment. In contrast, nuclear factor kappa-B (NF-κB), a transcription factor downstream of the TNF receptor (TNFR) but independent of the apoptotic pathway was not activated following FB₁ treatment. Taken together, this study suggested that the TNF signal transduction pathway (directly or indirectly) plays a role in FB₁-induced apoptosis. Further studies will be necessary to prove that the TNFR or downstream factors are directly affected by FB₁.

Materials and Methods

Cells Lines and Media

CV-1 cells were split at 1:5 ratio every 5 days. Mouse embryo fibroblasts (MEF) with a disrupted *p53* gene (*p53*^{-/-}) were obtained from E. Lee (University of Texas Southwestern Medical Center, San Antonio, Texas, USA) and T. Jacks (Massachusetts Institute of Technology, Cambridge, MA, USA). Normal MEF were prepared from Balb/C mice. MEF were split 5–7 times and then discarded. Cells were grown in Earle's modified Eagle's medium supplemented with 5% fetal bovine serum (FBS), penicillin (10 U/mL), and streptomycin (100 µg/mL) and were plated at a density of 5 × 10⁵ cells/100-mm plastic dish.

This article is based on a presentation at the International Conference on the Toxicology of Fumonisin held 28–30 June 1999 in Arlington, Virginia, USA.

Address correspondence to C. Jones, Center for Biotechnology, Dept. of Veterinary and Biomedical Sciences, University of Nebraska-Lincoln, East Campus Loop, Lincoln, NE 68583-0905 USA. Telephone: (402) 472-1890. Fax: (402) 472-9690. E-mail: cjones@unlnotes.unl.edu

This work was supported by funds from the Center for Biotechnology, Comparative Pathobiology Area of Concentration, the U.S. Department of Agriculture (USDA) (96-02186), and Elsa Pardee Foundation for Cancer Research. J. Ciacci-Zanella was supported by a scholarship from CNPq, Brazil. Yange Zhang was supported by funds from the Center for Biotechnology and the USDA (9802064).

Received 10 April 2000; accepted 17 January 2001.

Fumonisin B₁

FB₁ was obtained from R. Eppley (U.S. Food and Drug Administration, Washington, DC, USA) (> 99% pure) and was dissolved in calcium and magnesium-free, phosphate-buffered saline (PBS) (80 mM Na₂HPO₄; 20 mM NaH₂PO₄; 100 mM NaCl, pH 7.5). Three hours after the cells were plated, FB₁ was added to the media at a concentration of 5 or 25 μM.

Blueo-gal Co-Transfection and Analysis of Cell Death

Cells were plated at a density of 2×10^5 /well in 6-well plastic plates (35 mm/well) 12–16 hr prior to the transfection. Cells were then transfected with plasmid DNA containing the β-galactosidase gene [cytomegalovirus (CMV-β-gal)] by the calcium phosphate method (34). Samples were co-transfected with a mammalian expression plasmid that influences cell growth or apoptosis. A description of these plasmids is presented below. For each 35-mm well, 250 μL calcium phosphate solution (125 mM CaCl₂; 25 mM HEPES–NaOH, pH 7.1; 0.75 mM Na₂HPO₄–NaH₂PO₄, pH 7.0; 125 mM NaCl) and plasmid DNA mix were added to the cells. Five hours after transfection, cells were shocked with PBS in 20% glycerol for 4 min, then washed with PBS twice. Fresh medium containing 5% fetal calf serum and 5 mM sodium butyrate was added to the cells. Cells were incubated at 37°C for 16 hr, then passaged at a 1:5 ratio onto a 24-well dish. These cells were treated with 25 μM FB₁ or 20 μM C₆-ceramide (37°C for 48 hr), and β-gal expression was analyzed as described previously (27,35). Briefly, cells were rinsed with PBS, fixed with 2% formaldehyde, 0.2% glutaraldehyde in PBS for 5 min, then washed twice with PBS. Fixed cells were stained for 6–24 hr with 0.1% Blueo-gal (Gibco, Rockville, MD, USA) in a PBS solution containing 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, and 2 mM MgCl₂. After being rinsed in PBS, positive cells were observed microscopically and the number of stained blue cells counted. At least five fields per plate were counted, and the average number of cells per field was calculated.

Plasmids

pCMVCpIAP and pcDNA3/p35 are plasmids that contain baculovirus anti-apoptotic genes (36); these plasmids were obtained from L. Miller (University of Georgia, Athens, GA, USA). pcDNA/crmA (37) encodes a cowpox virus protein inhibitor of caspases and was obtained from L. Lou (University of Michigan Medical School, Ann Arbor, MI, USA). The adenovirus E1A or E1B 55-kDa encode proteins that bind Rb or p53, respectively, and were obtained from E. White (Rutgers University,

Piscataway, NJ, USA). The expression vector that encodes Bcl-2 was obtained from J. Reed (La Jolla Cancer Research Center, La Jolla, CA, USA). CMV-β-gal was purchased from Clontech (Palo Alto, CA, USA). Human immunodeficiency virus (HIV) long terminal repeat (LTR) and HIVΔNFκB were obtained from C. Wood (University of Nebraska, Lincoln, NE, USA). Plasmid preparations were obtained by cesium chloride purification (38).

Nuclear DNA Fragmentation Analysis

Cell cultures were treated with 5 μM FB₁ for 6, 12, 24, or 48 hr. Cells were then collected with a plastic cell scraper, suspended in TKMC buffer (10 mM Tris, pH 7.5; 10 mM KCl; 1 mM MgCl₂; 5 mM CaCl₂) containing 0.5% TX-100. Cells were lysed by treatment with 150 μg/mL of proteinase K, 100 mg RNase A, and 0.1% sodium dodecyl sulfate (SDS). Genomic DNA was extracted with a phenol–chloroform–isoamyl alcohol solution (50:49:1). DNA samples were electrophoresed in a 1.5% agarose gel using TBE (0.1 M Tris, 0.1 M boric acid, 0.025 M EDTA, pH 8.3). DNA in the agarose gel was denatured with 1.5 M NaCl, 0.5 M NaOH for 30 min at room temperature, then neutralized by incubating with 3.0 M NaCl and 0.5 M Tris, pH 5.2, for 25 min. After the neutralization step was repeated, gels were rinsed in 2× SSC (20 × SSC is 3 M NaCl and 0.3 M citric acid) and blotted onto a nylon membrane (Hy Bond+, Amersham). The DNA transferred to the membrane was hybridized with a monkey genomic DNA

probe. The probe was radiolabeled by random priming method with ³²P by an enzymatic reaction catalyzed by the Klenow enzyme (New England Biolabs, Beverly, MA, USA). Prehybridization was performed at 65°C in 5× SSPE (0.75 M NaCl, 0.05 M sodium phosphate, 0.005 M EDTA), 0.5% bovine serum albumin, 0.5% polyvinylpyrrolidone and 1% SDS for 2 hr. Hybridization was carried out for 6–18 hr at 65°C by using 2×10^7 dpm of radiolabeled probe diluted in hybridization buffer. Filters were washed 3 times at room temperature and once at 65°C for 30 min in 1× SSPE, 1% SDS. Filters were then dried and exposed to film.

Measurement of Cyclin-Dependent Kinase Activity

Dishes were washed with PBS and cells were collected, and suspended in 500 μL of lysis buffer (20 mM HEPES, pH 7.9; 0.4 M NaCl; 1 mM EDTA; 10 mM dithiothreitol; 1 mM phenylmethylsulfonyl fluoride; 25% glycerol). Cell lysate was kept on ice for 20 min and lysed by two freeze/thaw cycles. Cells were centrifuged for 10 min at 12,000 rpm, and the supernatant was kept at –80°C. Immunoprecipitations were performed with 150 μg cell lysates for 3–4 hr at 4°C; 1 μg of antibody was used. Immunocomplexes were precipitated with protein A-Sepharose beads (Sigma, St. Louis, MO, USA) and washed 4 times with washing buffer (10 mM Tris–HCl, pH 8.0; 50 mM NaCl; 1 mM EDTA; 0.5% nonidet P40) (30). Immunocomplexes were washed in 1× kinase buffer and the pellet was




Figure 1. Induction of apoptosis by FB₁. (A) CV-1 cells were transfected with plasmid pCMV-β-gal. After transfection, cells were treated with 25 μM FB₁ for 48 hr, fixed, and stained with Blueo-gal for 24 hr. Cultures treated with PBS are designated as controls. Magnification ×100. (B) CV-1 cells were treated with 25 μM FB₁ for 24 or 48 hr. High molecular weight DNA was prepared from CV-1 cells and electrophoresed on a 2% agarose gel; Southern blot analysis was performed using monkey DNA as a probe. Cultures not treated with FB₁ are designated as "C." Molecular weight markers are shown to the right.

suspended in 10 μ L of the same buffer (10 \times kinase buffer: 500 mM Tris, 250 mM Mg acetate, 25 mM EDTA). The kinase reaction contained 10 μ Ci γ -³²P-adenosine triphosphate (ATP), 0.1 M ATP, 2.7 μ g of histone H1, and 100 μ g crude extract diluted in 1 \times kinase buffer. After 30 min at 30°C, the reaction was stopped by addition of 25 μ L of SDS–polyacrylamide gel electrophoresis (PAGE) loading buffer. Reaction products were analyzed by SDS–PAGE, and the gel was dried and autoradiographed. Kinase activity was measured with a PhosphorImager instrument (Molecular Dynamics, Sunnyvale, CA, USA).

Analysis of Chloramphenicol Acetyltransferase Activity

CV-1 cells were transfected with the designated plasmids by calcium phosphate transfection as described previously (27,34,39). Following transfection, cultures were treated with 5 μ M FB₁. Forty hours after transfection, cells were washed in PBS and a cell-free lysate was prepared by three freeze–thaw cycles in 0.25 M Tris (pH 7.8). Chlorophenicol acetyltransferase (CAT) enzymatic activity was measured as described previously (39). After thin-layer chromatography, the amount of ¹⁴C-chloramphenicol (CM), acetylated or unacetylated, was measured with a PhosphorImager device.

Statistical Analysis

Statistical analyses were performed using Instat (Sigma Plot, Chicago, IL, USA), a personal computer software program. Results




Figure 2. Interference of FB₁-induced apoptosis in CV-1 cells. CV-1 cells were co-transfected with plasmid pCMV- β -gal (2 μ g DNA) and plasmids expressing the indicated apoptotic regulatory proteins (2 μ g of the indicated plasmid). After transfection, cells were treated with 25 μ M FB₁ for 48 hr, fixed, and stained with Blue-gal for 24 hr. The number of β -gal+ cells in five fields was determined. The percentage of β -gal+ colonies was normalized based on the number of blue cells in the untreated control. The data in this study were derived from five independent studies. The error bars show the standard error of the mean. The differences between E1B, p35, crmA, or CplAP and the control are significant ($p < 0.05$).

were considered statistically significant when the p value was < 0.05 .

Results

Identification of Genes That Inhibit Fumonisin B₁-Induced Apoptosis

By using a battery of well-accepted assays that identify apoptotic cells, several independent studies have concluded that FB₁ induces apoptosis in CV-1 cells (29) and human cells (26–29). To identify genes that regulate apoptosis, we used an assay based on co-transfecting cells with a β -gal expression plasmid (pCMV- β -gal) and a gene that regulates apoptosis (35,40,41). If a gene induces apoptosis, the number of β -gal+ cells decrease. Conversely, anti-apoptotic genes increase the number of β -gal+ cells following induction of apoptosis, relative to controls. FB₁ consistently reduced the number of β -gal+ cells in CV-1 cells (Figure 1A). Reduction of β -gal+ cells correlated with apoptosis because nucleosome-length DNA and higher molecular weight forms of degraded DNA accumulated 24 or 48 hr after treatment (Figure 1B, lanes 24 or 48). As expected, untreated CV-1 cells contained low levels of degraded DNA (Figure 1B, lane C).

In CV-1 cells, the baculovirus inhibitor of apoptosis (CpIAP) efficiently inhibited FB₁-induced apoptosis (Figure 2). The *Bcl-2* gene did not effectively inhibit apoptosis by FB₁. Two caspase inhibitors, crmA and p35, appeared to give slightly different results. p35 consistently inhibited FB₁-induced apoptosis slightly better than crmA in CV-1 cells. The adenovirus E1B gene encodes a 55-kDa protein that binds and inactivates the p53 tumor-suppressor protein [reviewed in (33)]. E1B protected cells from apoptosis by FB₁ but not as efficiently as CpIAP. As expected,

the adenovirus E1A gene induced apoptosis and FB₁ had little or no effect on this process. In summary, these studies indicated that CpIAP efficiently inhibited apoptosis by FB₁.

FB₁-Induced Apoptosis Does Not Require p53

To determine whether p53 was required for FB₁-induced apoptosis, studies were performed in MEF derived from p53^{−/−} mice and subsequently compared to results obtained in p53^{+/+} MEF. The studies presented in Figure 2 indicated that E1B did not completely prevent apoptosis by FB₁, suggesting p53 was important but not required. We were particularly interested in determining whether p53 was required for FB₁-induced apoptosis because of the importance p53 plays in apoptosis and cell growth. p53^{−/−} cells are ideal for these studies because they are low-passage cells that lack only p53, whereas many established cells lacking p53 have additional unidentified mutations. Treatment of p53^{−/−} cells with 25 μ M FB₁ for 24 hr led to the appearance of the typical DNA ladder characteristic of apoptosis (Figure 3A). When lower concentrations of FB₁ were used (5 μ M), apoptosis occurred but at a lower efficiency (data not shown). The β -gal transfection assay also demonstrated that 25 μ M FB₁ reduced the number of β -gal+ cells (Figure 3B), and CpIAP protected p53^{−/−} cells from apoptosis. p35 and CpIAP protected both MEF more efficiently from apoptosis relative to crmA. Bcl-2 protected p53^{−/−} MEF more effectively than p53^{+/+} MEF from FB₁-induced apoptosis. Although p53 was not absolutely required for apoptosis induced by FB₁, it appeared to have an effect on the ability of Bcl-2 to inhibit apoptosis.




Figure 3. Analysis of apoptosis in MEF after FB₁ treatment. (A) Genomic DNA was prepared from p53^{−/−} MEF after treatment with 25 μ M FB₁ for 24 hr. As a control, DNA was prepared from untreated cells (U). DNA was separated on 2% agarose gels, and the DNA was stained with ethidium bromide. The position and size (Kb) of the marker DNA (M) is indicated. (B) p53^{−/−} or p53^{+/+} MEF were co-transfected with pCMV- β -gal (2 μ g DNA) and a plasmid expressing the indicated apoptotic regulatory proteins (2 μ g). Cultures were treated with 25 μ M FB₁ after transfection. The results are the mean of five independent experiments. The arrow bars show the standard error of the mean. The differences between p35, Bcl-2, or CplAP and the control are significant ($p < 0.05$).




Figure 7. Measurement of cdk2 activity in CV-1 and COS-7 cells after FB₁ treatment. Total cell lysate was prepared from untreated or FB₁-treated CV-1 and COS-7 cells (5 μM of FB₁ for 3, 24, and 48 hr). Cdk2/cyclin complexes were immunoprecipitated with specific antibodies directed against the Cdk2 (Santa Cruz Biotech, Santa Cruz, CA, USA). Immunocomplexes were collected by incubation with protein A-Sepharose beads. glutathione S-transferase-Rb was used as a substrate to measure Cdk2 activity present in immunocomplexes as described previously (30). Following incubation with ³²P-γ-ATP, the proteins were electrophoresed on 10% SDS-PAGE, and the dried gel was autoradiographed. The results shown are the mean of four independent experiments.

FB₁-induced apoptosis. p53 transactivates expression of BAX (46), a pro-apoptotic gene. We hypothesize that in the absence of p53, BAX levels are lower, and under these circumstances Bcl-2 can efficiently inhibit murine fibroblasts from FB₁-induced apoptosis. It is also possible that Bcl-2 effectively inhibits apoptosis if an unknown cofactor is present.

FB₁-induced apoptosis was efficiently inhibited by CpiAP in the cell lines tested. CpiAP prevents apoptosis by interfering with the TNF/Fas pathway or binding certain caspases [reviewed in (33)]. Consequently, we hypothesized that the TNF/Fas pathway may be involved with FB₁-induced apoptosis. The TNFR1 recruits caspase 8, resulting in proteolytic activation of caspase 8, which subsequently activates a caspase cascade (Figure 4). The finding that caspase 8 was cleaved following FB₁ treatment (Figure 5) supports the hypothesis that the TNF/Fas pathway was activated. CpiAP also associates with the signaling molecule TNFR-associated factor (TRAF) and functions as a component of the TNFR signaling complex (47). TNF-α binds and activates TNFR, thus recruiting a TRAF-CpiAP complex to the cytoplasmic domain of TNFR. The TRAF-IAP complex consequently interferes with death signals activated by TNF. The recent finding that a TNFR-associated protein (TRAP)-2 is induced in CV-1 cells after FB₁ treatment lends support for the involvement of TNFR (48). Because CpiAP can also bind to several caspases and inhibit their protease activity (42), it is possible that inactivation of certain

caspases by CpiAP inhibits FB₁-induced apoptosis.

Although p35 and crmA are both caspase inhibitors, p35 inhibits a broader spectrum of caspases compared to crmA (49). IAP family members physically interact with caspase 3, 7, and 9 [reviewed in (33,42); Figure 4]. crmA has been reported to bind to caspase 8, but not caspase 9. crmA partially prevented apoptosis following FB₁ treatment, suggesting that the caspase 8 pathway is not the exclusive determinant in apoptosis. Our results cannot rule out the possibility that FB₁ treatment leads to activation of caspase 9, which is a proximal caspase in mitochondria-mediated apoptosis. Unlike caspase 8, we have not been able to demonstrate that caspase 9 was cleaved following FB₁ treatment (data not shown). Because caspase 9 activation requires interaction with active Apaf-1, but not proteolytic activation (50), further experiments will be necessary to determine if the caspase 9 signaling pathway is also involved with FB₁-induced apoptosis.

The association of TNFR with other factors, TNFR-associated death domain, TRAF2, Fas-associated death domain, or DAXX, can lead to apoptosis or NF-κB activation (41,51), which prevents cell death. The finding that FB₁ treatment did not lead to NF-κB (Figure 6) or AP-1 activation (52) suggested that FB₁ treatment selectively activated components of the TNF pathway leading to cell death. When FB₁ is injected subcutaneously into mice (53), TNF-α activity increases. A TNF-α-like activity is also induced in swine after FB₁ injection (54). Induction of TRAP2 in CV-1 cells but not COS-7 cells (48) suggested that TRAP2 plays an important role in FB₁-mediated apoptosis. Taken together, we hypothesize that induction of a TNF-like pathway in FB₁-treated cells has relevance to its toxic and carcinogenic properties. Future experiments will focus on identifying the factors in the TNF pathway that are induced by FB₁.

REFERENCES AND NOTES

- Burgess LW, Dodman RL, Pont W, Mayers P. *Fusarium* diseases of wheat, maize, and grain sorghum in Eastern Australia. In: *Fusarium Diseases, Biology, and Taxonomy* (Nelson PE, Tousson TA, Cook RJ, eds). University Park, PA:Pennsylvania State University Press, 1981:64–76.
- Cassini R. *Fusarium* diseases of wheat and corn in Western Europe. In: *Fusarium Diseases, Biology, and Taxonomy* (Nelson PE, Tousson TA, Cook RJ, eds). University Park, PA:Pennsylvania State University Press, 1981:56–63.
- Cook RJ. *Fusarium* diseases of wheat and other small grains in North America. In: *Fusarium Diseases, Biology, and Taxonomy* (Nelson PE, Tousson TA, Cook RJ, eds). University Park, PA:Pennsylvania State University Press, 1981:39–52.
- Cook RJ. *Fusarium* diseases in the People's Republic of China. In: *Fusarium Diseases, Biology, and Taxonomy* (Nelson PE, Tousson TA, Cook RJ, eds). University Park, PA:Pennsylvania State University Press, 1981:52–55.
- Kommedahl T, Windels CE. Root-, stalk-, and ear-infecting *Fusarium* species on corn in the USA. In: *Fusarium Diseases, Biology, and Taxonomy* (Nelson PE, Tousson TA, Cook RJ, eds). University Park, PA:Pennsylvania State University Press, 1981:94–103.
- Maric A. *Fusarium* diseases of wheat and corn in Eastern Europe and the Soviet Union. In: *Fusarium Diseases, Biology, and Taxonomy* (Nelson PE, Tousson TA, Cook RJ, eds). University Park, PA:Pennsylvania State University Press, 1981:94–103.
- Sun S-K, Snyder WC. The Bakanae disease of the rice plant. In: *Fusarium Diseases, Biology, and Taxonomy* (Nelson PE, Tousson TA, Cook RJ, eds). University Park, PA:Pennsylvania State University Press, 1981:104–113.
- Merrill AH, Wang E, Gilchrist DG, Riley RT. Fumonins and other inhibitors of de novo sphingolipid biosynthesis. *Advin Lipid Res* 26:215–234 (1993).
- Merrill AH, Liotta DC, Riley RT. Fumonins: fungal toxins that shed light on sphingolipid function. *Trends Cell Biol* 6:218–224 (1996).
- Spiegel S, Merrill AH Jr. Sphingolipid metabolism and growth regulation: a state of the art review. *FASEB J* 10:1388–1397 (1996).
- Sydenham EW, Gelderblom WCA, Thiel PG, Marasas WFO. Evidence for the natural occurrence of fumonisin B₁, a mycotoxin produced by *Fusarium moniliforme* in corn. *J Agric Food Chem* 38:285–290 (1990).
- Ueno Y, Iijima K, Wang S-D, Sugiyama Y, Sekijima M, Tanaka T, Chen C, Yu S-Z. Fumonisin as a possible contributory risk factor for primary liver cancer: a 3-year study of corn harvested in Haimen, China by HPLC and ELISA. *Food Chem Toxicol* 35:1143–1150 (1997).
- Marasas WFO. Mycotoxicological investigations on corn produced in esophageal cancer areas in Transkei. In: *Cancer of the Esophagus*, Vol 1. Boca Raton, FL:CRC Press, 1982:29–40.
- Gelderblom WCA, Kriek NPJ, Marasas WFO, Thiel PG. Toxicity and carcinogenicity of the *Fusarium moniliforme* metabolite, fumonisin B₁, in rats. *Carcinogenesis* 12:1247–1251 (1991).
- Gelderblom WCA, Semple E, Marasas WFO, Farber E. The cancer initiating potential of the fumonisin-B mycotoxins. *Carcinogenesis* 13:433–437 (1992).
- Jaskiewicz K, van Rensburg SJ, Marasas WFO, Gelderblom WCA. Carcinogenicity of *Fusarium moniliforme* culture media in rats. *J Natl Cancer Inst* 78:321–325 (1987).
- Gelderblom WCA, Jaskiewicz K, Marasas WFO, Thiel PG, Horak RM, Vleggaar R, Kriek NPJ. Fumonins-novel mycotoxins with cancer promoting activity produced by *Fusarium moniliforme*. *Appl Environ Microbiol* 54:1806–1811 (1998).
- Marasas WFO, Kellerman TS, Pienaar JG, Naudé TW. Leukoencephalomalacia: a mycotoxicosis of Equidae caused by *Fusarium moniliforme* Sheldon. *Onderstepoort J Vet Res* 43:113–122 (1976).
- Yoo HS, Norred WP, Showker J, Riley RT. Elevated sphingoid bases and complex sphingolipid depletion as contributing factors in fumonisin-induced cytotoxicity. *Toxicol Appl Pharmacol* 138:211–218 (1996).
- Harrison LR, Colvin B, Greene JT, Newman LE, Cole JR. Pulmonary edema and hydrothorax in swine produced by fumonisin B₁, a toxic metabolite of *Fusarium moniliforme*. *J Vet Diagn Invest* 2:217–221 (1990).
- Voss KA, Chamberlain WJ, Bacon CW, Norred WPA. A preliminary investigation on renal and hepatic toxicity in rats fed purified fumonisin B₁. *Natural Toxins* 1:222–228 (1993).
- Riley RT, Hinton DM, Chamberlain WJ, Bacon CW, Wang E, Merrill AH Jr, Voss KA. Dietary fumonisin B₁ induces disruption of sphingolipid metabolism in Sprague-Dawley rats: a new mechanism of nephrotoxicity. *J Nutri* 124:594–603 (1994).
- Gumprecht LA, Marcucci A, Weigel RM, Vesonder RF, Riley RT, Showker JL, Beasley VR, Haschek WM. Effects of intravenous fumonisin B₁ in rabbits: nephrotoxicity and sphingolipid alterations. *Natural Toxins* 3:395–403 (1995).
- Lim CW, Parker HM, Vesonder RF, Haschek WM. Intravenous fumonisin B₁ induces cell proliferation and apoptosis in the rat. *Natural Toxins* 4:34–44 (1996).
- Sharma RP, Dugley RR, Voss KA. Demonstration of in-situ apoptosis in mouse liver and kidney after short-term repeated exposure to fumonisin B₁. *J Comp Pathol* 117:371–381 (1997).
- Tolleson WH, Dooley KL, Sheldon WG, Dale Thurman J, Buccì TJ, Howard PC. The mycotoxin fumonisin induces apoptosis in cultured human cells and in livers and kidneys of rats. In: *Fumonins in Food (Advances in Experimental Medicine and Biology)* (Jackson LS, DeVries JW, Bullerman LB, eds). New York:Plenum Press, 1996:392,237–250.
- Ciacchi-Zanella JR, Jones C. Fumonisin B₁, a mycotoxin contaminant of cereal grains, induces apoptosis via the tumor necrosis factor pathway and caspase activation but does not require p53. *Food Chem Toxicol* 37:703–712 (1999).

28. Schmelz EM, Dombrink-Kurtzman MA, Roberts PC, Kozutsumi Y, Kawasaki T, Merrill AH Jr. Induction of apoptosis by fumonisin B₁ in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. *Toxicol Appl Pharmacol* 148:252 (1998).
29. Wang H, Jones C, Ciacci-Zanella J, Holt T, Gilchrist DG, Dickman M. Fumonisin and AAL toxins: sphinganine analog mycotoxins induce apoptosis in monkey kidney cells. *Proc Natl Acad Sci U S A* 93:3461–3465 (1996).
30. Ciacci-Zanella JR, Merrill AH Jr, Wang E, Jones C. Characterization of cell cycle arrest by fumonisin B₁ in CV-1 cells. *Food Chem Toxicol* 36:791–804 (1998).
31. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. *Cell* 82:405–414 (1995).
32. Zhou BB, Li H, Yuan J, Kirschner MW. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. *Proc Natl Acad Sci USA* 95:6785–6790 (1998).
33. White E. Life, death, and the pursuit of apoptosis. *Genes Dev* 10:1–15 (1996).
34. Graham TL, Van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. *Virology* 52:456–467 (1973).
35. Kumar S, Kinoshita M, Noda M, Copeland NG, Jenkins NA. Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the *Caenorhabditis elegans* cell death gene *ced-3* and the mammalian IL-1 β -converting enzyme. *Genes Dev* 8:1613–1626 (1994).
36. Clem RJ, Miller LK. Control of programmed cell death by the baculovirus genes *p35* and *iap*. *Mol Cell Biol* 14:5212–5222 (1994).
37. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM. Yama/CPP32b, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. *Cell* 81:801–809 (1995).
38. Sambrook J, Fritsch EF, Maniatis T. *Molecular Cloning: A Laboratory Manual*, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
39. Zhang Y, Dickman MB, Jones C. The mycotoxin fumonisin B₁ transcriptionally activates the *p27* promoter through a *cis*-acting element containing two Sp1 binding sites. *J Biol Chem* 274:12367–12371 (1999).
40. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF- κ B activation. *Cell* 81:495–504 (1995).
41. Liu Z-G, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1-effector functions: JNK activation is not linked to apoptosis while NF- κ B activation prevents cell death. *Cell* 87:565–576 (1996).
42. Deveraux QL, Reed JC. IAP family proteins—suppressors of apoptosis. *Genes Dev* 13:239–252 (1999).
43. Martin D, Siegel R, Zheng L, Lenardo M. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACH α 1) death signal. *J Biol Chem* 273:4345–4349 (1998).
44. Mosca JD, Bednarik DP, Raj NBK, Rosen CA, Sodroski JG, Heseltine WA, Hayward GS, Pitha PM. Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a transacting factor encoded by herpes simplex virus type 1. *Proc Natl Acad Sci U S A* 84:7408–7412 (1987).
45. Levkau B, Koyama H, Raines EW, Clurman BE, Herrem B, Orth K, Roberts JM, Ross R. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of cdk2: role of a caspase cascade. *Mol Cell* 4:553–563 (1998).
46. Miyashita T, Reed JC. Tumor suppressor *p53* is a direct transcriptional activator of the human *bax* gene. *Cell* 80:293–299 (1995).
47. Duckett CS, Li F, Wang Y, Tomaselli KJ, Thompson CB, Armstrong RC. Human IAP-like protein regulates programmed cell death downstream of Bcl-XL and cytochrome *c*. *Mol Cell Biol* 18:608–615 (1998).
48. Zhang Y, Jones C, Dickman MB. Identification of differentially expressed genes following treatment of monkey kidney cells with the mycotoxin fumonisin B₁. *Food Chem Toxicol* 39:45–53 (2001).
49. Orth K, Dixit VM. Bik and Bak induce apoptosis downstream of crmA but upstream of inhibitor of apoptosis. *J Biol Chem* 272:8841–8844 (1997).
50. Stennicke HR, Deveraux QL, Humke EW, Reed JC, Dixit VM, Salvesen GS. Caspase-9 can be activated without proteolytic processing. *J Biol Chem* 274:8359–8362 (1999).
51. Hsu H, Hong-Bing S, Ming-Gui P, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. *Cell* 84:299–308 (1996).
52. Huang C, Dickman M, Henderson G, Jones C. Repression of protein kinase C and stimulation of cyclic AMP response element by fumonisin, a fungal encoded toxin which is a carcinogen. *Cancer Res* 55:1655–1659 (1995).
53. Dugyala RR, Sharma RP, Tsunoda M, Riley R. Tumor necrosis factor- α as a contributor in fumonisin B₁ toxicity. *J Pharmacol Exp Ther* 285:317–324 (1998).
54. Guzman RE, Bailey K, Casteel SW, Turk J, Rottinghaus G. Dietary *Fusarium moniliforme* culture material induces *in vitro* tumor necrosis factor- α like activity in the sera of swine. *Immunopharmacol Immunotoxicol* 19:279–289 (1997).